Global Mental Health Summit

• 11:30 AM–12:30 PM  “Technology & Innovation: AI, Social Responsibility & the American Ibogaine Initiative” This session will connect Andrew Romero InferenceFrame’s AI infrastructure with the policy and clinical mission of the American Ibogaine Initiative, with Co-Host MyungHi S. Lee and KRFI Questors Hyperledger Technologies and GCET LLC.  Key discussion areas include:

​

• AI-enhanced investment frameworks for Ibogaine deployment

• Public–private partnership models supporting mental health reform

• Responsible funding strategies for bipartisan state-level Ibogaine bills

• Ethical scaling, oversight, and corporate social responsibility

• Building national infrastructure for Ibogaine-based mental health interventions

​

• Together, the speakers outline how AI, biotechnology, and responsible investment can accelerate safe, equitable, and evidence-based Ibogaine access for veterans, Indigenous communities, and Americans facing mental health and addiction crises. Andrew Romero leads the development of high-reliability AI at InferenceFrame, where he designs and deploys advanced structured reasoning systems that strengthen decision-making in high-stakes environments. His work centers on Neuro-Symbolic (NeSy) approaches that integrate mathematical and logical reasoning, enabling AI systems to perform with greater precision and significantly reduced data requirements. InferenceFrame’s technology has been used to generate actionable insights for companies, investment funds, and research organizations, supported by strategic institutional funding. The company has also established cost-sensitive licensing agreements, allowing scalable access to its reasoning systems. These AI platforms demonstrate strong performance across diverse domains, including:

​

• Financial markets & capital allocation

• Robotics & autonomous systems

• Mathematical and scientific discovery

• Risk assessment and high-stakes decision support

​

• Andrew has also developed a suite of AI-driven investment banking tools, supporting capital structuring, due diligence, and near-automated deal execution. These technologies help reduce operational bottlenecks and increase accuracy in financial decision-making. InferenceFrame’s systems are adopted through partnerships with major FINRA-member firms, including GT Securities, where Andrew serves as Director.

​

• 12:30 - 2:00 PM: ​ Moderated Paul Sladkus, and MyungHi S. Lee, with this session features collaborative framework for an Ibogaine Clinical R&D Alliance focused on FDA/MHRA/EMEA/ANVISA–registered clinical trial reporting and mechanism-of-action research.  The discussion highlights the KRFI Questors open-source clinical data platform, designed to address a persistent challenge in psychiatric research: fewer than 10% of clinical studies adequately assess double blinding integrity, as a foundational element of clinical trial design. The transparent, shared, and high-quality data, the field faces limitations in cost efficiency, reproducibility, and the ability to resolve the consequences of unblinding on data interpretation—issues that are especially critical for advancing Ibogaine and psychedelic-based mental health therapeutics.  The patient with placebo will experience withdrawal and possible unpredictable adverse reactions for the participants.

​

• Questors aims to establishing the Independent Ibogaine & Psychedelic Clinical Evidence Assessment Working Group (I&P CEA-WG). As clinical programs grow in complexity—particularly those integrating psychotherapy with pharmacological interventions—KRFI is convening an Independent Ibogaine and Psychedelic Clinical Evidence Assessment Working Group (I & P CEA-WG).

• This online data review platform generative reporting by the research institutes with an parallel track on policy and legal advisory group conducted at the  Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics,.  Independent Psychedelic Evidence Assessment Working Group (ICEA-WG).works with parallel track with online CTMS with institutional partnership and safety and pharmacovigilance and technical platform to aid the institutions, practitioners, and research community.

​

• Current State of the National Ibogaine Consortium endeavors by Bryan Hubbard and Rick Perry Co-founders of the Americans for Ibogaine and its role in a Public–Private Sector Partnership in Ibogaine Clinical Research.  The New York State Ibogaine Research Bill Action Plan for January 2026, This announcement aims to address the including:

  • Upcoming NYS Senate hearings featuring Ibogaine testimonials

  • Coordinated state-level action plans in NYS, Texas, Arizona, Ohio, and Colorado

  • Responses from state authorities across the United States

​

• Policy and Mental Health Strategy: The discussion will focus on mental health policy initiatives in New York State, exploring the allocation of $12 billion USD toward mental health and addiction programs. Special emphasis will be placed on the NYS Ibogaine Research Bill, led by Bipartisan Senate sponsors Natalie Rodriguez (D) and Jacob Ashby (R) during the January 2026 Hearing.

​​​

• Biography of Keynote Speakers

​

• Andrew Romero MBA is the Founder and Principal of InferenceFrame and a Director at GT Securities, where he serves as Managing Director for the Global Mental Health Security Fund. His work integrates investment banking with advanced data science and AI, particularly in the development of structured reasoning systems designed for reliability in high-stakes environments. Through InferenceFrame, Andrew has led the creation of AI and data-driven technologies that support situational reasoning, grounded in mathematical and logical frameworks and informed by a NeSy (Neuro-Symbolic) approach. These systems are engineered to deliver dependable performance while significantly reducing data requirements. InferenceFrame has provided insights and analytical solutions to numerous companies, investment funds, and research organizations, and has established cost-sensitive licensing agreements for its proprietary reasoning platforms. Strategic institutional funding has supported the continued development and demonstrable performance of these systems across diverse domains. Andrew’s work spans multiple application areas, including financial markets, robotics, and mathematical and scientific discovery, with a wide range of future use cases under exploration. In the investment banking domain, he has developed AI-driven solutions for capital structuring, due diligence, and near-automated deal execution. His technology is partnered with several leading FINRA-member firms, including GT Securities, where his expertise supports innovative financial solutions at the intersection of AI and global mental health strategy.

​

• MyungHi S. Lee, DAOM, is the Founder and CEO of the Knowledge Recovery Foundation/Institute (KRFI), established in 1989 with a focus on global health challenges including malaria, tuberculosis, and HIV/AIDS. Under her leadership, KRFI has addressed major policy and implementation barriers related to Artemisinin Combination Therapy (ACT), contributing to advancements in artemisinin supply—such as the development of supercritical fluid extracts (SFE), high-yield cultivars, Drug Master Files (DMFs), and ACT clinical trials in Africa. Her collaborative work with Dr. Lee Sang Wook supported the WHO Secretary General’s Rollback Malaria initiative from 2004 to 2010, particularly in areas of ABS-IP policy and ACT deployment.  MyungHi is a Natural Products Pharmacognosist with specialized expertise in supercritical extraction technologies, prodrug formulation, and orally disintegrating tablet (ODT) manufacturing across the UK and Korea. She has more than 25 years of experience navigating regulatory compliance and has organized joint conferences with KSEA on GMP manufacturing, DSEA Act compliance, and FDA regulatory pathways for botanical drug development.  Currently, KRFI is expanding its work in Questors clinical trial management systems (CTMS) and reporting platforms for Ibogaine and psychedelics. KRFI’s CRO division, KRFI Questors, is dedicated to education in drug safety and pharmacovigilance, and actively supports the development of FDA clinical trials for Ibogaine targeting opioid and substance use disorders (OUD/SUD).

​

• Presenter:  Reverend Paul Sladkus, All Faiths and Spiritual, Host of over 7,500 Good News Broadcast Programs, with over 1,000 on Health and Wellness.  Former Executive with CBS and PBS/Channel 13 TV.  Worked on the original Award Winning Brain Series for PBS. www.pausetheworldforpeace.org. THERE IS NO PEACE WHEN YOU ARE A DRUG ADDICT. ​​